THE BIGGEST SILENT REVOLUTION  IN VACCINATION SINCE THE RABIES VACCINE

THERAVECTYS is a privately-owned company located in France, translating 20 years+ of research on lentiviral vectors into actionable innovation and bringing a spectacular paradigm shift into vaccinology. Founded by pioneer inventor Dr Pierre Charneau, as a spin-off of the Pasteur Institute, TheraVectys leverages its unique proprietary platform to deliver remarkably safe and efficient T-cell vaccines as a response to critical unmet medical needs. THERAVECTYS’ technology and worldwide license domain has an almost unlimited number of applications in infectious diseases, virally-induced cancers and cancers, and is probably the biggest silent revolution in vaccination since the discovery of the vaccine against rabies by Louis Pasteur. Our purpose: ‘profoundly transform global health’. Our approach: strategic industrial partnering for leading our PoC-validated vaccine-candidates to clinical trials and to market.

Vision

Curing major chronic infections and cancers at an affordable cost, and finally tackling the global HIV epidemic

Science

Lentiviral proprietary platform to design safe and efficient T-cell vaccines

Portfolio

From Preclinical Proof-of-Concepts in Infectious Diseases, Virus-Induced Cancers and Solid Tumors to Clinical Development

At Theravectys we believe our lentiviral vector platform is the answer to twenty years of vaccine failures because our vaccine-candidates elicit efficient cellular immune responses and have demonstrated great safety profile. With the potential to develop prophylactic as well as therapeutic vaccines, we are on the edge of treating major chronic infections and cancers at an affordable cost, and in particular, finally tackling the global HIV epidemic.

Our mission is to design the safest and most efficient T-cells vaccines and partner with major players to develop and deliver them as quick as possible to patients threatened by critical conditions with no treatment alternative.

We are convinced that given the potential of lentiviral vectors we should not limit our development to a few diseases only. On the contrary, to maximise the chance of patients benefiting from our vaccines, we dedicate our resources to preclinical POC in a broad range of indications and we rely on systematic partnering and tight collaboration to move our products successfully through clinical stages and regulatory approval.

A high-leverage portfolio Strategy at the service of our greater purpose

Strat 1

THIS IS HOW WE POSITION OURSELVES TO BECOME GAME CHANGERS IN THE LANDSCAPE OF GLOBAL HEALTH.